Compare SRTS & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRTS | ICCC |
|---|---|---|
| Founded | 2010 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5M | 55.5M |
| IPO Year | 2016 | 1987 |
| Metric | SRTS | ICCC |
|---|---|---|
| Price | $4.06 | $5.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 170.7K | 17.9K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $35,609,000.00 | $27,769,304.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $47.33 | N/A |
| P/E Ratio | ★ N/A | $18.36 |
| Revenue Growth | N/A | ★ 16.49 |
| 52 Week Low | $3.03 | $4.10 |
| 52 Week High | $9.31 | $7.60 |
| Indicator | SRTS | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 40.21 |
| Support Level | $3.81 | $4.70 |
| Resistance Level | $4.34 | $5.36 |
| Average True Range (ATR) | 0.29 | 0.28 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 29.02 | 22.83 |
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.